As of Nov 2, 2026: Robert W. Duggan (CEO, SMMT) reported 2 buys for $51.4M in the last 12 months (Form 4). SMMT's Quality Score is -3. Scores as of 9:30 PM ET, 15 minutes behind.

Robert W. Duggan

Co-Chief Executive Officer of Summit Therapeutics

2 stock trades in the last 12 months, shares they bought or sold themselves (not grants or options).

Bought$51.4M12 months Sold$012 months Last filedJun 12a buy

From SEC Form 4s · Insiders have 2 business days to file a trade

Every trade Robert W. Duggan reported

Newest first, as filed

Stock	Trade	Amount	Trade	Shares	Traded Filed
SMMTSummit Therapeutics	Buy	$50Mat $13.12	Buy$50Mat $13.12	3,810,000 at $13.12	Jun 12filed Jun 12SEC filing
SMMTSummit Therapeutics	Buy	$1.5Mat $14.60	Buy$1.5Mat $14.60	100,000 at $14.60	Jun 4filed Jun 4SEC filing

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

See all 2 tradesSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Robert W. Duggan's companies

Where they file, with the stock's Quality Score

Company	Title, as filed	Trades	Quality Score
SMMTSummit TherapeuticsCEO	Co-Chief Executive Officerfiled Jun 12	2	-3

Big buys by CEOs and CFOs

An alert when a CEO or CFO buys $1M or more of their company's stock.

Set an alert

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Use this page

Kept by Andrew Gomes, Breakaway's founder, from the SEC's Form 4 filings. Updated Jun 12, 2026.

Free to reuse with a link to this page.

How to cite

Breakaway, Robert W. Duggan: Co-Chief Executive Officer at SMMT, Jun 12, 2026, getbreakaway.com/insiders/robert-w-duggan-smmt

Journalists: email support@getbreakaway.com for the data behind this page.

Others who file at Summit Therapeutics

Insider trades by person